| Name | Title | Contact Details |
|---|
RWJBarnabas Health is the most comprehensive health care delivery system in New Jersey, treating over 3 million patients a year. The system includes eleven acute care hospitals – Clara Maass Medical Center in Belleville, Community Medical Center in Toms River, Jersey City Medical Center in Jersey City, Monmouth Medical Center in Long Branch, Monmouth Medical Center Southern Campus in Lakewood, Newark Beth Israel Medical Center in Newark, RWJUH in New Brunswick and Somerville, RWJUH- Hamilton, RWJUH- Rahway and Saint Barnabas Medical Center in Livingston; three acute care children`s hospitals and a leading pediatric rehabilitation hospital (Children`s Specialized Hospital), a freestanding 100-bed behavioral health center, ambulatory care centers, geriatric centers, the state`s largest behavioral health network, comprehensive home care and hospice programs, fitness and wellness centers, retail pharmacy services, a medical group, multi-site imaging centers and four accountable care organizations. RWJBarnabas Health is New Jersey`s second largest private employer – with more than 32,000 employees, 9,000 physicians and 1,000 residents and interns – and routinely captures national awards for its outstanding quality and safety.
Namaste Technologies is a global leader in the sale of medical cannabis consumption devices. Namaste has nine offices with multiple distribution centers around the globe and operates over 30 websites under various brands. Namaste has developed innovative technology platforms including NamasteMD.com, Canada`s first ACMPR compliant telemedicine application. The company is focused on patient acquisition through NamasteMD and intends on building Canada`s largest database of medical cannabis patients. The company`s subsidiary, CannMart Inc. is an ACMPR Licensed Producer with a “sales-only” license, whereby the company will offer a large variety of medical cannabis sourced from domestic and international producers. Namaste will continue to develop and acquire innovative technologies which will provide value to the Company and to its shareholders as well as to the broader cannabis market.
UT Medical Group is the private practice arm of the University of Tennessee Health Science Center (UTHSC) faculty. Because the physicians in our group are actively involved in teaching and research, they remain current with the latest medical developments. As a not-for-profit, non-tax-supported group practice, UT Medical Group is dedicated to quality patient care, medical education, and medical research. This allows us to offer many unique, advanced health care services to people in the Mid-South at competitive prices. Ties to UTHSC allow the physicians at UT Medical Group access to the latest treatments, special protocols and labs, as well as a broad spectrum of professionals with advanced degrees in nursing, nutrition, pharmacology, psychology, and more. This involvement benefits not only our patients' treatments, but keeps the physicians at the top of their fields.
Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.
Ra Pharma combines novel insights into complement and other innate immunity pathways with leadership in macrocycle technology to transform the lives of patients with life threatening disorders.